Rapid infectious disease test Xpert® vanA/vanB

for Enterococcuslaboratoryfor PCR

Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1 In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1 High-risk patients colonized with VRE have 24 times the increased infection risk2 Infections caused by VRE are associated with high mortality3 VRE has an impact on patient length of stay, and in turn, hospitalization costs3 The Solution Rapid molecular detection of vanA/vanB genes associated with VRE colonization Fast, active screening of high-risk patients to support infection control measures aimed at reducing transmission risk The Impact The Xpert vanA/vanB test facilitates efficient infection control surveillance programs, published studies demonstrated:4 – 93% reduction of turn around time from 70.5h with chromogenic agar culture to 4.6h – High negative predictive value supports identification of non-colonized patients – Associated with a reduction in the number of identified contact patients in published studies – One published economic analysis reported lower overall costs in a institutional setting when molecular screening was used compared with culture Some studies reported fewer isolation days following the adoption of rapid molecular screening compared with culture.5